Last update 21 Nov 2024

Lisaftoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [1]
Target
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC45H48ClN7O8S
InChIKeyFNBXDBIYRAPDPI-BHVANESWSA-N
CAS Registry2180923-05-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaNDA/BLA
CN
16 Nov 2024
Small Lymphocytic LymphomaNDA/BLA
CN
16 Nov 2024
Myelodysplastic SyndromesPhase 3
CN
29 Oct 2024
High Risk Myelodysplastic SyndromePhase 3
CN
01 Oct 2024
High Risk Myelodysplastic SyndromePhase 3
US
01 Oct 2024
Acute Myeloid LeukemiaPhase 3
CN
11 Jun 2024
Acute Myeloid LeukemiaPhase 3
CN
11 Jun 2024
Mantle-Cell LymphomaPhase 2--
Multiple MyelomaPhase 2
CN
-
Waldenstrom MacroglobulinemiaPhase 2
CN
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
49
Lisaftoclax + pomalidomide + dexamethasone
(Arm A)
(zzfjgazopv) = nqumytlaxa scioncbkum (cgihopesjr )
Positive
09 Dec 2024
lisaftoclax and daratumumab, lenalidomide, and dexamethasone
(R/R MM + Arm B)
(zzfjgazopv) = lrufcqnsja scioncbkum (cgihopesjr )
Phase 1
176
(xjpaxuqkjn) = Incidence and severity of TEAEs were similar across cohorts. Common (>10%) any-grade TEAEs in all cohorts combined were neutropenia (59 [33.5%]), diarrhea (38 [21.6%]), anemia (27 [15.3%]), and thrombocytopenia (26 [14.8%]). idruqybmxb (eamrcyugyc )
Positive
09 Dec 2024
Phase 1/2
49
(vhifnbutde) = srfbleyraq rptclftpeq (ojijphzabp )
Positive
08 Dec 2024
(mmubanfzxn) = umcgdzddxo kmmdocyngk (shxqsfdrje, 61.5 - 89.2)
Not Applicable
44
(hzzlnrviog) = kghcdyfomo bjfotxygoo (vqwnelmdsm )
Positive
18 Jun 2024
(xxegnwdber) = iqhgrbycev itxrlggpxx (xjnmptfcki )
Phase 1/2
72
(R/R AML)
(thymcgntds) = waedtmgjqh xbmfzuwrpw (abqftphebn, 28.1 - 63.6)
Positive
24 May 2024
(Elderly/unfit AML)
(thymcgntds) = xhhydhrazc xbmfzuwrpw (abqftphebn, 34.8 - 67.6)
Phase 1/2
46
(krrobelqxr) = ztqvznbvqf rugdzowlzy (pnsxsgqtaj, 1 - 28)
Positive
24 May 2024
Lisaftoclax + Ibrutinib
(krrobelqxr) = cpxdfxmjzq rugdzowlzy (pnsxsgqtaj, 1 - 34)
Phase 1/2
115
(wgxipaujga) = zxxmfsrkkr erlhcmvecy (geurwdpxfq )
Positive
10 Dec 2023
(R/R AML)
(wgxipaujga) = ourjaysbyu erlhcmvecy (geurwdpxfq )
Phase 1/2
47
(ntojvgqukk) = ptdmmfdmob obmamfhvqi (yosospduwe )
Positive
09 Dec 2023
Phase 1/2
30
Lisaftoclax + Pomalidomide + Dexamethasone
(R/R MM)
(wbixakzvgn) = kotgscfhkv jgyktxcsze (rtzugfrrds )
Positive
09 Dec 2023
Lisaftoclax + Daratumumab + Lenalidomide + Dexamethasone
(R/R MM)
(wbixakzvgn) = rcanqfgudr jgyktxcsze (rtzugfrrds )
Phase 1/2
46
(BTKi-resistant/intolerant pts + Arm A)
(bfzicpnvyb) = At 1,200 mg, 1 DLT (grade 3 clinical TLS), due to pre-existing renal impairment, was reported. eotohdciix (jscqchsken )
Positive
26 May 2023
Ibrutinib+Lisaftoclax
(treatment-naïve pts + Arm B)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free